Rigel Pharma (RIGL) Sees Wild Rollercoaster Pre-Open Trading Amid Data
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Rigel Pharma (RIGL) Pushes to Highs; Shares Up 53%
August 30, 2016 12:37 PM EDTRigel Pharma (NASDAQ: RIGL) pushes to the highs of the session. Shares are up 53% to $4.03.
... MoreRigel Pharmaceuticals (RIGL) PT Raised to $11 at Piper Jaffray
August 30, 2016 8:53 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and raised his price target to $11.00 (from $10.00) following data this morning.
For an analyst ratings summary and ratings history on Rigel Pharmaceuticals... More
Rigel Pharmaceuticals (RIGL) PT Raised to $6 at BMO Capital Following Positive ITP Study
August 30, 2016 8:21 AM EDTBMO Capital analyst Do Kim reiterated an Outperform rating and raised his price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $6.00 (from $4.00) following positive results from the first of two Phase III trials for fostamatinib in chronic ITP.
"We believe the significant 18% response rate... More
Rigel Pharma (RIGL) Could Rise Up to 90% Today - JP Morgan
August 30, 2016 7:27 AM EDTJPMorgan is making positive comments on Rigel Pharma (NASDAQ: RIGL) following this morning's phase 3 data and said the stock could rise 60-90% today.
... MoreRigel Pharma (RIGL) Oral Spleen Tyrosine Kinase (SYK) Inhibitor Met Primary Endpoint in Phase 3 Study
August 30, 2016 7:01 AM EDTRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP). The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261). A stable platelet response was defined as achieving greater than 50,000 platelets per uL of blood on at least four of the last six scheduled visits between weeks 14 and 24... More